Sun Pharma announces USFDA approval for Generic Eloxatin and Imitrex

These oxaliplatin injections, 50 mg and 100 mg packed in single use vials, are therapeutically equivalent to Eloxatin injections from sanofi-aventis.

Sun Pharmaceutical Industries announced that USFDA has granted approvals for two Abbreviated New Drug Applications (ANDAs), generic version of Eloxatin , oxaliplatin for injection and generic version of Imtrex , sumatriptan succinate tablets. Sun Pharma shares 180 days exclusivity for generic version of Eloxatin.

These oxaliplatin injections, 50 mg and 100 mg packed in single use vials, are therapeutically equivalent to Eloxatin injections from sanofi-aventis. Oxaliplatin injections have annual sales of approximately USD 2.3 billion in the US. Oxaliplatin is an anticancer used in the treatment of colon and rectal cancer.

These sumatriptan succinate tablets, 25 mg (base), 50 mg (base) and 100 mg (base) are therapeutically equivalent to Imitrex tablets from GlaxoSmithkline. Sumatriptan succinate tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.

This article was first uploaded on August twelve, twenty nine, at forty minutes past ten in the morning.